Compare CVRX & EDAP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CVRX | EDAP |
|---|---|---|
| Founded | 2000 | 1979 |
| Country | United States | France |
| Employees | N/A | N/A |
| Industry | Biotechnology: Electromedical & Electrotherapeutic Apparatus | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 171.7M | 163.4M |
| IPO Year | 2021 | 1998 |
| Metric | CVRX | EDAP |
|---|---|---|
| Price | $7.83 | $4.14 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 5 | 3 |
| Target Price | ★ $11.20 | $8.50 |
| AVG Volume (30 Days) | ★ 410.6K | 59.0K |
| Earning Date | 05-07-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 23.02 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $56,651,000.00 | N/A |
| Revenue This Year | $16.78 | N/A |
| Revenue Next Year | $19.73 | $7.15 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 10.45 | N/A |
| 52 Week Low | $4.37 | $1.21 |
| 52 Week High | $13.34 | $5.05 |
| Indicator | CVRX | EDAP |
|---|---|---|
| Relative Strength Index (RSI) | 57.05 | 45.61 |
| Support Level | $6.76 | $3.64 |
| Resistance Level | $8.45 | $4.24 |
| Average True Range (ATR) | 0.62 | 0.38 |
| MACD | 0.08 | -0.06 |
| Stochastic Oscillator | 76.37 | 41.82 |
CVRx Inc is a commercial-stage medical device company focused on developing, manufacturing, and commercializing minimally invasive neuromodulation solutions for patients with cardiovascular diseases. Its proprietary platform technology, Barostim, is designed to leverage the power of the brain to address the imbalance of the Autonomic Nervous System, which causes heart failure and other cardiovascular diseases. Barostim provides Baroreflex Activation Therapy which in turn triggers an autonomic response to the heart. The majority of revenue is derived from the USA market.
Edap TMS SA is a holding company operating in three divisions namely, HIFU (High-Intensity Focused Ultrasound), ESWL (Extracorporeal ShockWave Lithotripsy), and Distribution. The HIFU division develops, manufactures, and markets devices for the invasive destruction of certain types of tumors using HIFU technology. It markets three HIFU devices: the Ablatherm, Ablatherm Fusion, and the Focal One. The ESWL division is engaged in the manufacturing, marketing, and servicing of its installed base of Sonolith range of lithotripters. The Distribution division markets products that are complementary to its globalized activity such as lasers, micro-ultrasound systems, and other medical products from third parties. Its geographical segments are Asia, France, United States, and Others.